Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model. -Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be...
APP Group Highlights Commitment to Sustainable Packaging with Foopak at Foodservice Australia 2025
JAKARTA, Indonesia, June 19, 2025 /PRNewswire/ -- Consumer demand is shaping the future of sustainable packaging in Australia, with 51% of consumers saying sustainability is important when making a purchase. This shift is driving companies to adapt...